Transitioning From Brand to Generic With Topical Products and the Importance of Maintaining the Formulation and Therapeutic Profiles of the Original Product: Focus on Clocortolone Pivalate 0.1% Cream

July 2014 | Volume 13 | Issue 7 | Supplement Individual Articles | 77 | Copyright © July 2014

James Q. Del Rosso DO FAOCDa and Leon H. Kircik MDb

aLas Vegas Skin and Cancer Clinics/West Dermatology Group, JDRx Dermatology LL C, Henderson, NV;
Touro University College of Osteopathic Medicine, Henderson, NV
bIndiana University School of Medicine, Indianapolis, IN; Icahn School of Medicine at Mount Sinai, New York, NY;
Physicians Skin Care, PLL C, Louisville, KY

table 2
matoses. Importantly, these findings were demonstrated with the clocortolone pivalate 0.1% cream containing the active TCS ingredient and not just with the cream vehicle alone. These results were confirmed in a second study of the same design.

Efficacy and Safety Data

Clocortolone pivalate 0.1% cream has been studied in multiple clinical trials for the treatment of a variety of CRDs. These trials were inclusive of 559 adult and pediatric patients who were ac-